8-KEarnings & ResultsRegulation FDExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 18, 2007)

Filed April 18, 2007For Securities:JNJ

Summary

This 8-K filing from Johnson & Johnson (JNJ), filed on April 18, 2007, provides investors with updated financial performance information for the first quarter ended April 1, 2007, and revised full-year 2007 guidance. The company reported on sales of key products and franchises, supplementing their earnings press release with additional detail. A key takeaway for investors is the upward revision of JNJ's full-year 2007 adjusted earnings per share (EPS) guidance to a range of $4.02-$4.07, excluding certain charges and the impact of in-process R&D from the Conor Medsystems acquisition. This optimistic outlook reflects strong first-quarter performance, effective cost management, and strategic financing initiatives. Furthermore, Johnson & Johnson raised its guidance for 2007 full-year operational sales growth to an anticipated range of 12.0% to 12.5%. This increased growth projection incorporates the pro forma impact of the Pfizer Consumer Healthcare acquisition. Investors should note that the provided guidance, particularly the EPS, excludes specific items such as in-process research and development and other special items. The filing also reiterates the company's standard forward-looking statement disclosures, highlighting potential risks and uncertainties that could affect actual results.

Key Highlights

  • 1Johnson & Johnson (JNJ) announced an upward revision to its 2007 full-year adjusted EPS guidance to $4.02-$4.07.
  • 2The company also increased its 2007 full-year operational sales growth guidance to 12.0%-12.5%.
  • 3The revised guidance reflects strong Q1 2007 financial performance and effective cost control measures.
  • 4Guidance updates incorporate the pro forma impact of the Pfizer Consumer Healthcare acquisition.
  • 5Adjusted EPS guidance excludes in-process R&D charges and other special items.
  • 6The filing includes supplemental sales data for key products and franchises for Q1 2007.
  • 7The acquisition of Conor Medsystems, Inc. (completed in February 2007) has a dilutive effect on EPS guidance, excluding in-process R&D.

Frequently Asked Questions

The most significant update is the company's raised full-year 2007 guidance. Johnson & Johnson increased its forecast for adjusted earnings per share (EPS) to a range of $4.02-$4.07 and its operational sales growth to 12.0%-12.5%. This suggests confidence in the company's performance for the remainder of the year.

The improved guidance is attributed to Johnson & Johnson's solid financial performance in the first quarter of 2007, continued effective cost control measures, and the strategic impact of its financing strategy. The pro forma inclusion of the Pfizer Consumer Healthcare acquisition also contributes to the sales growth expectations.

Yes, the adjusted EPS guidance specifically excludes in-process research and development (R&D) charges, including those related to the Conor Medsystems acquisition, as well as other special items. Investors should be aware of these exclusions when comparing the guidance to reported figures.

This 8-K filing incorporates by reference Exhibit 99.1, which contains supplemental tables of sales for key products and franchises for the first quarter of 2007, and Exhibit 99.2, which presents pro forma operational sales growth rates. These exhibits provide further detail on the company's performance.